What it's for (Indications)
- Enalapril maleate + hydrochlorothiazide is a fixed-dose combination medication primarily indicated for the treatment of essential hypertension (high blood pressure).
- This combination therapy is generally reserved for patients whose blood pressure is not adequately controlled with monotherapy (treatment with a single agent) or for whom the combination is deemed appropriate as initial therapy.
- Enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic, work synergistically to reduce blood pressure through distinct but complementary mechanisms.
- The rationale for this combination is to enhance antihypertensive efficacy while often minimizing dose-dependent side effects that might occur with higher doses of either component alone.
- It is particularly useful in patients who require more aggressive blood pressure lowering or who have conditions that benefit from both an ACE inhibitor and a diuretic, such as certain forms of volume-dependent hypertension.
- Before initiating this therapy, a thorough assessment of the patient's cardiovascular risk profile, kidney function, and electrolyte status is crucial.
- This combination is not typically indicated for the initial treatment of uncomplicated hypertension if monotherapy is expected to be sufficient, but rather for cases requiring dual therapy to achieve target blood pressure goals as defined by current clinical guidelines.
- The convenience of a single tablet for two active ingredients can also contribute to improved patient adherence.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of enalapril maleate + hydrochlorothiazide must be individualized based on the patient's blood pressure response, renal function, and tolerance to each component. Typically, the fixed-dose combination should only be initiated after a patient has been stabilized on individual components or when monotherapy has proven insufficient. The usual starting dose for patients not adequately controlled on monotherapy is often one tablet once daily. Dosage adjustments, if necessary, should be made after careful assessment of blood pressure and patient tolerability, usually at intervals of several weeks. It is crucial to monitor renal function and electrolyte levels, especially potassium, before and during treatment, as patients with impaired renal function may require lower doses or alternative therapies. The maximum recommended daily dose should not be exceeded. Abrupt discontinuation of this medication is not advised, as it may lead to a rebound increase in blood pressure. Healthcare professionals must refer to the specific product information and current clinical guidelines for detailed dosing recommendations, including special considerations for elderly patients or those with specific comorbidities, ensuring the dose is optimized for efficacy and safety. |
Safety & Warnings
Common Side Effects
- The use of enalapril maleate + hydrochlorothiazide can be associated with various side effects, reflecting the pharmacological actions of both components.
- Common adverse reactions attributed to enalapril include persistent dry cough, dizziness, fatigue, headache, and orthostatic hypotension, particularly after the first dose.
- Hydrochlorothiazide can frequently lead to electrolyte disturbances such as hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia, as well as hyperglycemia, hyperuricemia, and increased urination.
- More serious, albeit less common, side effects include angioedema (swelling of the face, lips, tongue, and/or larynx), which requires immediate medical attention and discontinuation of the drug.
- Renal dysfunction, symptomatic hypotension, blood dyscrasias, and hepatic impairment are also potential serious adverse events.
- Photosensitivity reactions, pancreatitis, and acute myopia with secondary angle-closure glaucoma are rare but reported with hydrochlorothiazide.
- Patients should be advised to report any concerning symptoms to their healthcare provider promptly.
- Regular monitoring of blood pressure, renal function, and serum electrolytes is imperative throughout the treatment duration to identify and manage potential adverse effects proactively.
- A comprehensive understanding of the full spectrum of potential side effects is vital for patient safety and optimal therapeutic outcomes.
Serious Warnings
- Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue enalapril maleate and hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Enalapril maleate + hydrochlorothiazide carries several critical warnings and precautions.
- It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioedema, anuria, or known hypersensitivity to any component of the product or to sulfonamide-derived drugs.
- Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with ACE inhibitors, angiotensin receptor blockers (ARBs), or aliskiren is generally not recommended due to an increased risk of hypotension, hyperkalemia, and worsening renal function, especially in patients with diabetes or pre-existing renal impairment.
- Symptomatic hypotension, particularly in volume-depleted patients or those with severe heart failure, may occur.
- Close monitoring is required, especially after the initial dose.
- Hyperkalemia can develop, particularly in patients with renal impairment, diabetes mellitus, or those receiving concomitant potassium-sparing diuretics or potassium supplements.
- Hydrochlorothiazide can cause dose-related decreases in serum potassium, requiring electrolyte monitoring.
- Renal function should be assessed before and periodically during therapy.
- This medication is contraindicated during pregnancy (particularly the second and third trimesters) due to the risk of fetal harm and mortality.
- It should be used with caution in patients with severe aortic stenosis or hypertrophic cardiomyopathy.
- Patients should be cautioned against concomitant use of NSAIDs, which can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics and ACE inhibitors, and potentially worsen renal function.
- All healthcare providers must thoroughly review the prescribing information for a complete list of warnings and precautions.
How it Works (Mechanism of Action)
The antihypertensive efficacy of enalapril maleate + hydrochlorothiazide is achieved through the combined, distinct mechanisms of its two active components. Enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor, exerts its primary action by preventing the conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor and a key stimulator of aldosterone secretion, which leads to sodium and water retention. By inhibiting ACE, enalapril reduces systemic vascular resistance, lowers blood pressure, and decreases aldosterone-mediated volume expansion. It also inhibits the degradation of bradykinin, a vasodilator, which may contribute to its blood pressure-lowering effect. Hydrochlorothiazide, a thiazide diuretic, acts primarily in the cortical diluting segment of the kidney's distal convoluted tubule. Here, it inhibits the active reabsorption of sodium and chloride ions from the tubular lumen by blocking the Na+/Cl- cotransporter. This inhibition increases the excretion of sodium, chloride, and consequently water, leading to a reduction in plasma volume and, over time, a decrease in peripheral vascular resistance. The synergistic action of an ACE inhibitor reducing vasoconstriction and volume overload, combined with a diuretic reducing fluid volume, provides a comprehensive approach to blood pressure control. This dual mechanism often results in superior blood pressure reduction compared to monotherapy with either agent, while potentially mitigating dose-dependent side effects.
Commercial Brands (Alternatives)
No other brands found for this formula.